Urogen Pharma Ltd Quick Ratio (URGN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Urogen Pharma Ltd   (NASDAQ: URGN)

Urogen Pharma Ltd 's Quick Ratio

URGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.74 below Urogen Pharma Ltd average.

Within Major Pharmaceutical Preparations industry 299 other companies have achieved higher Quick Ratio than Urogen Pharma Ltd in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 636 to 1504.

Explain Quick Ratio?
How much Cash & cash equivalents URGN´s has?
What are URGN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

URGN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 20.58 % 15.14 % 0.63 % 27.95 % 37.21 %
Y / Y Cash & cash equivalent Change 16.23 % 5.69 % -6.96 % -28.04 % -57.76 %
Quick Ratio MRQ 1.74 2.09 3.32 1.96 1.81
URGN's Total Ranking # 1504 # 636 # 720 # 637 # 471
Seq. Current Liabilities Change 17.41 % 9.35 % 4.74 % -10.33 % 12.11 %
Seq. Cash & cash equivalent Change -1.8 % -31.3 % 77.73 % -3.07 % -10.7 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 300
Healthcare Sector # 525
Overall Market # 1504


Quick Ratio Statistics
High Average Low
24.04 5.24 0.68
(Mar 31 2019)   (Jun 30 2023)




Financial Statements
Urogen Pharma Ltd 's Current Liabilities $ 62 Millions Visit URGN's Balance sheet
Urogen Pharma Ltd 's Cash & cash equivalent $ 108 Millions Visit URGN's Balance sheet
Source of URGN's Sales Visit URGN's Sales by Geography


Cumulative Urogen Pharma Ltd 's Quick Ratio

URGN's Quick Ratio for the trailling 12 Months

URGN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 15.39 % 18.68 % 26.87 % 40.39 % 40.42 %
Y / Y Cash & cash equivalent TTM Growth -5.28 % -27.08 % -31.07 % -19.69 % -12.65 %
Quick Ratio TTM 2.24 2.28 2.34 2.4 2.73
Total Ranking TTM # 3810 # 3732 # 2383 # 2368 # 1878
Seq. Current Liabilities TTM Growth 5.33 % 3.62 % 0.16 % 5.55 % 8.33 %
Seq. Cash & cash equivalent TTM Growth 3.33 % 1.32 % -2.61 % -7.1 % -20.45 %

Quick ratio ranking by company, industry and sector >> Back to URGN Financial Strength Comparisons >> Go to Compare URGN Quick Ratio to its Competitors

  News about Urogen Pharma Ltd Quick Ratio

UroGen Pharma Advances Bladder Cancer Fight with Milestone Phase 3 Trial Enrollment Amid Industry Challenges,

UroGen Pharma Reaches Major Milestone in Fight Against Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., July 07, 2025 UroGen Pharma Ltd. (Nasdaq: URGN), a pioneering biotech company focused on developing innovative treatments for urothelial and specialty cancers, has announced a significant milestone in its endeavor to revolutionize cancer treatment. The company completed patient enrollment for its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a cutting-edge formulation designed for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Advancements in Bladder Cancer TreatmentThe completion of enrollment in the UTOPIA clinical trial marks a pivotal moment for UroGen. The trial seeks to address a critical medical need in the management of LG-IR-NMIBC, a cancer known for its high recurrence rate and potential for progression. UGN-103 offers a promising therapeutic option that could transform the treatment landscape for patients grappling with this challenging condition.

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $61.92 millions, cumulative Quick Ratio decreased to 2.24 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Urogen Pharma Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3732 to 3810.

Explain Quick Ratio?
How much Cash & cash equivalents URGN´s has?
What are URGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 431
Healthcare Sector # 880
Within the Market # 3810


trailing twelve months Quick Ratio Statistics
High Average Low
14.2 4.59 1.48
(Mar 31 2019)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Calcimedica Inc   4.71 $ 18.600  Millions$ 3.950  Millions
Kala Bio inc   4.70 $ 7.229  Millions$ 1.538  Millions
Septerna Inc   4.69 $ 372.322  Millions$ 79.316  Millions
Viking Therapeutics Inc   4.57 $ 501.663  Millions$ 109.656  Millions
Camp4 Therapeutics Corporation  4.51 $ 86.398  Millions$ 19.142  Millions
Rein Therapeutics Inc   4.49 $ 43.627  Millions$ 9.709  Millions
Quantum Cyber N v   4.46 $ 13.415  Millions$ 3.005  Millions
Maia Biotechnology Inc   4.41 $ 27.596  Millions$ 6.258  Millions
Azitra Inc   4.40 $ 6.728  Millions$ 1.531  Millions
Cypherpunk Technologies Inc   4.39 $ 7.624  Millions$ 1.737  Millions
Rigel Pharmaceuticals Inc  4.35 $ 225.347  Millions$ 51.858  Millions
Biohaven Ltd   4.28 $ 267.866  Millions$ 62.658  Millions
Longeveron Inc   4.20 $ 18.104  Millions$ 4.307  Millions
Vistagen Therapeutics Inc   4.15 $ 46.439  Millions$ 11.192  Millions
Gyre Therapeutics Inc   4.12 $ 86.289  Millions$ 20.957  Millions
Seaport Therapeutics Inc   4.11 $ 64.423  Millions$ 15.674  Millions
Prelude Therapeutics Inc  3.99 $ 151.757  Millions$ 38.042  Millions
Alx Oncology Holdings Inc  3.97 $ 22.753  Millions$ 5.731  Millions
Actinium Pharmaceuticals Inc  3.94 $ 36.473  Millions$ 9.260  Millions
Veru Inc   3.88 $ 23.880  Millions$ 6.156  Millions
Gain Therapeutics inc  3.81 $ 13.084  Millions$ 3.434  Millions
Bolt Biotherapeutics Inc   3.79 $ 29.823  Millions$ 7.867  Millions
Acurx Pharmaceuticals inc   3.72 $ 10.656  Millions$ 2.865  Millions
Maplight Therapeutics Inc   3.71 $ 71.633  Millions$ 19.294  Millions
Aptevo Therapeutics Inc   3.47 $ 17.997  Millions$ 5.188  Millions
Ataibeckley Inc   3.43 $ 168.807  Millions$ 49.221  Millions
Dogwood Therapeutics inc   3.40 $ 9.628  Millions$ 2.831  Millions
Tvardi Therapeutics Inc   3.39 $ 30.865  Millions$ 9.113  Millions
Biomea Fusion Inc   3.32 $ 34.824  Millions$ 10.483  Millions
Abeona Therapeutics Inc   3.32 $ 146.826  Millions$ 44.233  Millions

Date modified: 2026-09-09T22:40:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.